Bradykinin receptors on vascular smooth muscle may play an important role in regulating the endogenous effects of the vascular kallikrein-kinin system. The present study examined the effect of cyclic nucleotides on bradykinin-stimulated responses in cultured arterial smooth muscle cells. Short term stimulation (1 min) with cyclic AMP produced a variable inhibition of bradykinin-stimulated calcium mobilization which was lost in later passaged cells. However, long-term stimulation (24 h) produced a consistent increase in bradykininstimulated calcium mobilization in both early and late passaged cells. Further analysis demonstrated that chronic exposure to cAMP produced a twofold increase in both the number of cell surface bradykinin receptors and in bradykinin-stimulated phosphoinositide hydrolysis. The increase in bradykinin receptors was time dependent (> 7 h) and blocked by protein synthesis inhibitors, suggesting that cAMP enhanced the synthesis of new bradykinin receptors. The increase in bradykinin receptor binding and calcium mobilization was also stimulated by cholera toxin, forskolin, and isobutylmethylxanthine, but not isoproterenol or prostaglandin E2. Of considerable interest, prolonged exposure to cAMP inhibited both angiotensin II and arginine vasopressin-stimulated phosphoinositide hydrolysis and intracellular calcium mobilization. In summary, prolonged treatment with cAMP selectively stimulates the synthesis and expression of bradykinin receptors on arterial smooth muscle while decreasing the responsiveness to vasoconstrictor agonists such as angiotensin II and vasopressin. 
Introduction
Evolving evidence has suggested that an endogenous kallikrein-kinin system, analogous to the tissue renin-angiotensin is present within the vascular wall (1) (2) (3) . Kininogenase activity as well as messenger RNA for kallikrein has been found in freshly isolated vascular tissue and the entire system (kininogen, kininogenase, and kininase activity) is localized within smooth muscle cells cultured from the vascular wall (1) (2) (3) . The kinins which are generated can bind to bradykinin recep-tors which have been found on both endothelial cells as well as on cultured vascular smooth muscle cells (4) (5) (6) . Kinin receptors in both cell types are coupled to activation ofa phosphoinositide-specific phospholipase C which in endothelial cells leads to increases in intracellular calcium and the release of nitrosovasodilators and prostaglandins (4, 6, 7) . The tissue level ofkinins are further controlled by proteases such as kininase II (angiotensin converting enzyme) and other kininases which are present on endothelial cells and vascular smooth muscle cells (8) . Although knowledge of the vascular kallikrein-kinin is relatively new, studies with the recently developed specific bradykinin B2 receptor antagonists have suggested that this system may be important in a number ofpathophysiologic processes involving the vascular system (9, 10) . For instance, studies using bradykinin antagonists have suggested that endogenous bradykinin may play a role in both the antihypertensive and the antiproliferative actions of angiotensin converting enzyme inhibitors (9, 10) . However, considerable work remains to determine the exact role of the vascular kallikrein-kinin system.
Most ofthe recent interest in bradykinin has focused on its ability to stimulate the release of vasoactive substances from the endothelium (11) . However, there is evidence that bradykinin can also exert endothelium-independent effects on many isolated arteries and veins ( 12, 13) . Depending upon the species ofanimal and the site oforigin ofthe vessel, bradykinin has been shown to produce both relaxation and contraction in endothelium-denuded vessels ( 13 ) . This underscores the heterogeneity of possible responses to bradykinin and demonstrates that in addition to its potent endothelial-dependent effects, bradykinin also has direct effects upon the vascular smooth muscle. These vascular smooth muscle effects of bradykinin are likely to be very important to understanding the role ofthe kinins generated by the endogenous kallikrein-kinin system within the vessel wall.
To better understand the role of the endogenous vascular kallikrein-kinin system, we have analyzed the biochemical effects of bradykinin on arterial smooth muscle cells cultured from rat mesenteric arteries; a vessel which displays both vasodilatation and contraction to bradykinin ( 14) . These studies have demonstrated that bradykinin binds to a B2 receptor coupled to activation of a phosphoinositide-specific phospholipase C and activation of protein kinase C (5, 6) . During the course of these studies it was noted that the response to bradykinin tended to decrease with serial passage and we looked for factors which might be responsible for modulating bradykinin responsiveness. Since the vascular responses to bradykinin are likely to be influenced by endothelial-derived substances which act by modulating cyclic nucleotide levels in vascular smooth muscle, we explored the effects ofcyclic nucleotides on bradykininstimulated calcium release. Preliminary results demonstrated that while short term exposure to cAMP had variable results, long term exposure produced a significant increase in bradykinin-stimulated calcium release (preliminary data were presented at the American Federation for Clinical Research meetings in April 1989 and published in abstract form [1989. Clin.
Res. 37 [21] :259A]. Subsequent results were also presented at the American Society for Cell Biology in December 1990 and published in abstract form [ 1990. J. Cell Bid. 111 (5) :215a]. This study was designed to further analyze the mechanism whereby cyclic nucleotides regulate bradykinin-stimulated calcium release in cultured arterial smooth muscle cells. The results demonstrate that long term exposure to agents which increase intracellular cAMP stimulated the synthesis of new bradykinin receptors coupled to activation of a phosphoinositide-specific phospholipase C. Moreover, this effect was selective for bradykinin and long term exposure to cAMP produced inhibition of both angiotensin II and arginine vasopressinstimulated phosphoinositide hydrolysis and calcium release.
Overall, the results demonstrate that cAMP can regulate bradykinin receptor synthesis and expression in cultured arterial smooth muscle cells. Cultured arterial smooth muscle cells. Arterial smooth muscle cells were isolated from the mesenteric artery of male Sprague Dawley rats (Sasco Co., Omaha, NE) and grown in culture as previously described (5, 6) . Immunofluorescent staining has demonstrated that passages 1-4 (P,-P4), uniformly express the smooth muscle specific isoform of actin, a-actin (5). Cultures were grown in minimal essential medium (MEM, containing Earle's salts) supplemented with 2 mM glutamine, 100 U/ml penicillin, 100 Ag/ml streptomycin, and 10% bovine calf serum (BCS). Studies were performed as soon as the cultures were confluent (5-8 d unreacted Na'25I removed with 20 ml of 4% acetic acid. The bound peptide was then eluted with 3-5 ml of methanol. The methanol was removed by drying under N2 and the peptide dissolved in 20 Ml of0.1% acetic acid. The radiolabeled peptide was purified by reverse phase HPLC (Beckman Instruments, Inc.) using a C,8 column (Beckman US ODS) with an acetonitrile gradient in water (containing 0.1% TFA) from 20-50% at a flow rate of 1 ml/min. All fractions were collected in a fraction collector (400 Al/tube). The mono-1251-labeled tracer eluted as a sharp peak ( -35% acetonitrile) which was collected and used for the binding studies. The monoiodinated peak was clearly separated from both the unlabeled peptide and the small fraction of diiodinated peptide. The tube containing the peak activity (typically 1-3 x 108 cpm/400 pl) was selected and diluted with an equal volume of methanol and stored at -200C. The '251-Tyr0 BK was used as soon as possible after the preparation but never more than 1 mo after the radioiodination.
Bradykinin (Fig. 1 A) . As the cells were passaged they lost bradykinin receptors (see below) and exhibited a decreased calcium response to stimulation by bradykinin (Fig. 1 B). In these latter passaged cells, the inhibitory effects of short term exposure to cAMP were no longer observed and now long term exposure to cAMP clearly induced a pronounced increase in bradykinin-stimulated calcium release (Fig. 1 B) . The effect of cAMP appeared to increase the early peak of bradykinin- stimulated calcium release whereas the later susta phase ofintracellular calcium was no different bet and cAMP-treated cells. In some experiments, pro ment with cAMP produced a significant bradyki in cells which had no baseline response to bradykii shown). There appeared to be a limit to this phen ever because 24 h ofexposure to cAMP did not ret siveness to bradykinin in cells which had lost all reto bradykinin for several passages. In the rema study we have focused on the mechanism underlb term effects of cAMP on bradykinin-stimulated lease.
Effect ofchronic cAMP on BK-stimulatedphos hydrolysis. As either cAMP or cGMP in cultured arterial smooth muscle cells. Fig. 10 demonstrates the effect of chronic treatment with these agents on BK-stimulated calcium release. With the exception of the receptor agonist, isoproterenol, which we have previously shown increases intracellular cAMP levels (5), all postreceptor agents which increase cAMP (cAMP, forskolin, and cholera toxin) produced a similar 2-2.5-fold increase in BKstimulated calcium release. Alternatively, agonists which increase intracellular cGMP (e.g., 8-bromo-cGMP and nitroprusside) had no significant effect on BK-stimulated calcium release. The results were further examined in Table I where we compared the effect of several of these agents to stimulate cAMP levels and enhance BK-receptor binding. Again, treatment with another receptor agonist, PGE2, produced a small increase in cAMP levels but did not increase BK receptor binding in most experiments. By contrast, chronic treatment with several post-receptor agonists which acted either by stimulating the production of cAMP (forskolin and cholera toxin) or preventing its breakdown (IBMX) produced larger increases in cAMP levels and significant 60 we examined the effect of chronic exposure to cAMP on All and AVP-stimulated calcium and phosphoinositide release. As shown in Fig. 1 1 , treatment of the cultured cells for 24 h with cAMP produced an increase in BK-stimulated calcium release but an opposite, inhibitory effect on both All-and AVP-stimulated calcium release. The mechanism of the inhibitory effect of cAMP was further analyzed by measuring angiotensin IIand vasopressin-stimulated phosphoinositide hydrolysis. As demonstrated in Fig. 12 , prolonged exposure to cAMP significantly enhanced BK-stimulated IP2 release but inhibited both All and AVP-stimulated IP2 release. Similar results were seen for measurement of IP3, however the results did not reach statistical significance (data not shown). The results demonstrate that prolonged exposure to cAMP selectively enhanced BK receptor synthesis and expression in arterial smooth muscle cells while inhibiting the effects of other vasoactive hormone receptors coupled to phosphoinositide-specific phospholipase C.
Discussion
The role of the recently discovered vascular kallikrein-kinin system is uncertain. However, studies using selective bradykinin antagonists have suggested that the vascular kallikreinkinin system may play a role in both the antihypertensive and antiproliferative actions of angiotensin converting enzyme inhibitors (9, 10) . These antihypertensive and antiproliferative effects of bradykinin on vascular smooth muscle are presumed to be due to the indirect action ofbradykinin to release vasoactive substances from the endothelium (10, 11) . However, in addition to the indirect endothelial effects ofbradykinin, there are also direct effects ofbradykinin upon vascular smooth muscle cells (5, 6, 12, 13 ). Since bradykinin is likely produced and released by vascular smooth muscle cells within the vessel wall, then the ultimate effects ofthe vascular kallikrein-kinin system will involve an interplay between the indirect (paracrine) effects of bradykinin to release vasoactive mediators from endothelial cells and the direct (autocrine) effects on vascular smooth muscle. The direct effects of bradykinin on vascular contr Figure 11 . Differential s-o1 -A cAMP effects of long-term ex- (6) . This suggests that the direct effects ofbradykinin on vascular smooth muscle may be similar to those produced by angiotensin II. Recent studies in the balloon-denuded carotid artery model of vascular damage seem to confirm this hypothesis (10) . While increases in bradykinin were shown to be beneficial to the antiproliferative effects of angiotensin converting enzyme inhibitors, probably by increasing the endothelial release of nitric oxide ( 10). The direct effects of bradykinin on vascular smooth muscle appeared to be similar to those of angiotensin II, since both the angiotensin II receptor antagonist, losartan as well as the bradykinin receptor antagonist, HOE 140 decreased neoinitimal proliferation ( 10) . The overall effect of cAMP can not be predicted however, since the effects ofcAMP on bradykinin receptor expression in endothelial cells is not yet known. Taken together, these observations suggest that prolonged increases in cyclic AMP could modulate the responsiveness of vascular smooth muscle cells by decreasing the responsiveness to known vasoconstrictor hormones, angiotensin II, and vasopressin while increasing the responsiveness to bradykinin. However, the ultimate effect ofthis shift in hormone responsiveness on the overall physiologic responses of the blood vessel remains to be explored.
Cyclic nucleotides are known to play a central role in modulating the responsiveness of vascular smooth muscle to vasoconstrictor agonists (21 ) . Although cAMP may exert a direct inhibitory effect on the contractile proteins (e.g., possibly by phosphorylation of MLCK) most evidence suggests that cyclic nucleotides act primarily by inhibiting vasoconstrictor-induced increases in intracellular calcium (22, 23) . Cyclic nucleotides can decrease hormone-stimulated increases in intracellular calcium via the following mechanisms: (a) by activating calcium pumps located on the sarcolemma and sarcoplasmic reticulum leading to a decrease in both basal and hormone-stimulated intracellular calcium (24, 25) ; (b) by inhibiting receptor-mediated activation of phospholipase C, possibly via phosphorylation of a small molecular weight G protein which couples the receptor to phospholipase C (26, 27) ; and (c) possibly by inhibiting the 'P3-mediated release of calcium from intracellular stores (28) . Our results in early passaged cells are also compatible with an inhibitory effect of cAMP on bradykinin-stimulated calcium release. However, this effect was variable and rapidly lost with further cell passage. Of interest, recent studies by Lincoln et al. (23) have suggested that the inhibitory effects of cAMP on agonist-induced increases in intracellular calcium may be mediated via activation of cGMP-dependent kinase, which was lost during the passage of vascular smooth muscle cells in culture. Loss of cGMP-dependent kinase or other factors might explain the variability we observed in the acute inhibitory effects of cAMP in our early passaged cells. In addition, since there was no inhibitory effect of cAMP (or cGMP, data not shown) in later passaged cells, the loss of cGMP kinase or other factors may be more rapid and complete in arterial smooth muscle cells cultured from the mesenteric artery than those traditionally obtained from rat aorta. Finally, it is of interest to note that the effects of cAMP are not always inhibitory on hormone-stimulated calcium mobilization. In particular, short term increases in cAMP have been shown to enhance bradykinin-stimulated calcium mobilization and nitric oxide release in cultured porcine endothelial cells (29) . These observations suggest that the acute effects of cAMP may differentially enhance the hormone-stimulated release of vasodilatory substances from the endothelium while inhibiting the effects of calcium-mobilizing vasoconstrictor agonists on the vascular smooth muscle.
The results of this study suggest that after prolonged exposure to cAMP, there is a dissociation between the increase in bradykinin receptor binding and bradykinin-stimulated calcium release in early passage cells. Several factors may account for this observation. First, as discussed above, cAMP may be exerting an inhibitory effect on bradykinin-stimulated calcium mobilization that may be present only in early passaged cells. In addition to the inhibitory mechanisms discussed above, we also noted that prolonged treatment with cAMP increased bradykinin-stimulated IP2 formation without measurable increases in IP3 formation. This might suggest that chronic cAMP has additional effects to increase the dephosphorylation of IP3 to IP2 or alter the metabolism of phosphatidylinositol 4,5-bisphosphate (PIP2) and phosphatidylinositol phosphate (PIP) by phospholipase C. Although cAMP can affect some of the enzymes involved in inositol phosphate metabolism, these particular effects of cAMP on inositol phosphate metabolism have not yet been reported (30) . An alternative possibility is that early passage cells already have maximal bradykinin-stimulated calcium release and further increases in receptor number or phosphoinositide hydrolysis will not elicit any further release ofintracellular calcium. Using image analysis to study the intracellular calcium response in individual cells, we have observed that in early passaged cells virtually all cells respond with large increases in intracellular calcium suggesting that the presence of additional receptors coupled to phosphoinositide turnover may not serve to significantly further enhance the release of calcium from intracellular stores (6) . However, in later passaged cells there are fewer cells responding to bradykinin and the response in each individual cell is lower. In these cells prolonged treatment with cAMP appears to cause an increase in both the number of cells responding to bradykinin and in the maximal response within each cell (B. S. Dixon and R. V. Sharma, unpublished observations). Further studies will be necessary to determine ifit is the increase in cAMP or saturation of calcium release mechanisms (or both) which produces the dissociation between increased bradykinin receptor expression and bradykinin-stimulated calcium release in early passages of cultured arterial smooth muscle cells.
Much less is known about the chronic effects of cyclic nucleotides on vascular responsiveness. In particular, there have been very few studies of the long term effects of cyclic nucleotides on hormone receptor expression in vascular smooth muscle cells. Colluci reported that 24 h of incubation with cAMP inhibited the synthesis of a I-adrenergic receptors in rabbit aortic smooth muscle cells (31 ) . Although norepinephrine-stimulated calcium efflux was not inhibited, the effect of prolonged exposure to cyclic nucleotides on norepinephrine-stimulated phosphoinositide hydrolysis and intracellular calcium release were not determined (31 ) . Studies in other cell types have demonstrated that prolonged exposure to cAMP can inhibit the synthesis of polypeptide hormones linked to activation of phosphoinositide hydrolysis (32, 33) . In particular, Guillon et al. (33) have shown that chronic treatment with agents that elevate intracellular cAMP produced a 50-60% decrease in both vasopressin and angiotensin II receptors in rat granulosa cells. The decrease in receptors was paralleled by a similar decrease in both vasopressin and angiotensin II-stimulated phosphoinositide hydrolysis (33) . These results are compatible with our observations and suggest that cyclic nucleotides may inhibit the synthesis of angiotensin II and vasopressin receptors in vascular smooth muscle as well. Overall, these results suggest that cAMP may inhibit the synthesis of receptors for several of the known vasoconstrictor hormones while stimulating the synthesis ofbradykinin receptors on vascular smooth muscle cells.
The mechanisms whereby cAMP regulates gene transcription are under active investigation (34) . One well described mechanism involves the phosphorylation and activation of a transcription factor (CREB) which binds to the cAMP response element (CRE, 5'-TGACGTCA). This cis-acting element has been shown to be present in a number of genes which are regulated by cAMP (34) . In addition, for some genes, cAMP also appears to act via a different cis-acting element known as the AP-2 (activator protein-2) binding site (34) . Nei (20) . Finally, it is noted in passing, that bradykinin receptor synthesis has also been shown to be stimulated several fold in ras-transformed fibroblasts (36). However, since ras-proteins do not appear to activate adenylate cyclase or produce significant increases in cAMP they presumably stimulate bradykinin receptor synthesis by a mechanism different than that observed in the present study (37) . Clearly additional studies will be necessary to determine the mechanism whereby cAMP stimulates bradykinin receptor synthesis and to evaluate the significance of these observations to interactions between the endothelium and arterial smooth muscle in vivo.
In summary, prolonged increases in cAMP stimulate the synthesis and expression of new cell surface bradykinin receptors coupled to activation of phosphoinositide hydrolysis and mobilization of intracellular calcium in cultured arterial smooth muscle cells. In distinct contrast, prolonged increases in cAMP significantly inhibit both angiotensin II-and vasopressin-stimulated phosphoinositide hydrolysis and calcium mobilization. These studies, suggest that prolonged increases in cAMP may shift the biologic responsiveness of vascular smooth muscle away from known vasoconstrictor hormones towards a cellular program regulated by bradykinin. However, the physiologic effects of these observations is not yet clear. Although there may be subtle differences in the transmembrane signaling pathways activated by bradykinin and angiotensin II, the overall effects of these hormones to increase intracellular calcium and activate protein kinase C appear to be the same. These studies may have important implications to mech-anisms whereby cyclic nucleotides regulate vascular contractility and proliferation. Moreover, they begin to provide a clearer understanding of the factors regulating the expression and function of bradykinin receptors on vascular smooth muscle cells.
